T lymphocyte activation through the C28 pathway is insensitive to inhibition by the immunosuppressive drug FK-506.
Nanomolar concentrations of the novel immunosuppressive drug FK-506 inhibit the proliferation of human T lymphocytes in vitro induced by mitogenic lectins or by monoclonal antibodies directed against the CD3 or CD2 surface antigens. However, the alternative pathway of T lymphocyte proliferation induced by monoclonal antibodies specific for CD28 together with phorbol esters is unaffected by FK-506.
Kay
J E
JE
Biochemistry Laboratory, School of Biological Sciences, University of Sussex, Brighton, U.K.
Benzie
C R
CR
D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D000911:Antibodies, Monoclonal / Q000494:pharmacology; D000945:Antigens, Differentiation, T-Lymphocyte; D018801:CD2 Antigens; D018106:CD28 Antigens; D017252:CD3 Complex; D006801:Humans; D007166:Immunosuppressive Agents / Q000494:pharmacology*; D066298:In Vitro Techniques; D008213:Lymphocyte Activation / Q000187:drug effects*; D008934:Mitogens / Q000494:pharmacology; D011948:Receptors, Antigen, T-Cell; D011971:Receptors, Immunologic; D013601:T-Lymphocytes / Q000187:drug effects* / Q000276:immunology; D016559:Tacrolimus
D000900:Anti-Bacterial Agents; D000911:Antibodies, Monoclonal; D000945:Antigens, Differentiation, T-Lymphocyte; D018801:CD2 Antigens; D018106:CD28 Antigens; D017252:CD3 Complex; D007166:Immunosuppressive Agents; D008934:Mitogens; D011948:Receptors, Antigen, T-Cell; D011971:Receptors, Immunologic; D016559:Tacrolimus